PCSK9 inhibitors: Going forward and beyond

被引：1
|
作者：
Attar, Armin [1 ]
机构：
[1] Shiraz Univ Med Sci, Dept Cardiovasc Med, TAHA Clin Trial Grp, Shiraz, Iran
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2021年 / 28卷 / 08期
关键词：
LDL-CHOLESTEROL; SECONDARY ANALYSIS; CLINICAL-EFFICACY; EVOLOCUMAB; SAFETY; STATIN;
D O I：
10.1177/2047487320916964
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：803 / 804
页数：2
相关论文
共 50 条
  • [21] PCSK9 inhibitors for treating hypercholesterolemia
    Pasta, Andrea
    Cremonini, Anna Laura
    Pisciotta, Livia
    Buscaglia, Angelo
    Porto, Italo
    Barra, Fabio
    Ferrero, Simone
    Brunelli, Claudio
    Rosa, Gian Marco
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (03) : 353 - 363
  • [22] Thumbs Up for PCSK9 Inhibitors
    Voelker, Rebecca
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2015, 314 (03): : 217 - 217
  • [23] PCSK9 inhibitors - clinical applications
    Schmidli, Robert
    AUSTRALIAN PRESCRIBER, 2016, 39 (05) : 168 - 170
  • [24] The Evolving Future of PCSK9 Inhibitors
    Rosenson, Robert S.
    Hegele, Robert A.
    Fazio, Sergio
    Cannon, Christopher P.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2018, 72 (03) : 314 - 329
  • [25] PCSK9 Inhibitors for Familial Hypercholesterolemia
    Lenahan, Christy M.
    Harringtoon, Deedra
    JNP-JOURNAL FOR NURSE PRACTITIONERS, 2016, 12 (08): : 577 - 578
  • [26] Therapeutic contribution of PCSK9 inhibitors
    Millan Nunez-Cortes, Jesus
    Pedro-Botet, Juan
    CLINICA E INVESTIGACION EN ARTERIOSCLEROSIS, 2016, 28 : 39 - 41
  • [27] Are PCSK9 Inhibitors Cost Effective?
    Max J. Korman
    Kjetil Retterstøl
    Ivar Sønbø Kristiansen
    Torbjørn Wisløff
    PharmacoEconomics, 2018, 36 : 1031 - 1041
  • [28] PCSK9 Inhibitors: The Evolving Future
    Jeswani, Bijay Mukesh
    Sharma, Shubhangi
    Rathore, Sawai Singh
    Nazir, Abubakar
    Bhatheja, Rohit
    Kapoor, Kapil
    HEALTH SCIENCE REPORTS, 2024, 7 (11)
  • [29] Cholesterol reduction with PCSK9 inhibitors
    Lambooij A.
    Huisarts en wetenschap, 2018, 61 (9) : 18 - 20
  • [30] EFFICACY BIOMARKER FOR PCSK9 INHIBITORS
    Laaksonen, R.
    Koistinen, K.
    Huuhilo, R.
    Tarasov, K.
    Hurme, R.
    Ekroos, K.
    Prat, A.
    Seidah, N.
    Janis, M.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 104 - 104
12345